# Phase 2 Study of TD-9855 to Treat Fibromyalgia

> **NCT01693692** · PHASE2 · COMPLETED · sponsor: **Theravance Biopharma** · enrollment: 392 (actual)

## Conditions studied

- Fibromyalgia

## Interventions

- **DRUG:** TD-9855 Group 1
- **DRUG:** TD-9855 Group 2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01693692
- **Lead sponsor:** Theravance Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2014-01
- **Final completion:** 2014-04
- **Target enrollment:** 392 (ACTUAL)
- **Last updated:** 2022-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01693692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01693692, "Phase 2 Study of TD-9855 to Treat Fibromyalgia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01693692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*